Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
Breakthrough treatment after years of only modest progress in heart failure
+Print Archive
South GP CME
Breakthrough treatment after years of only modest progress in heart failure
Wednesday 28 August 2019, 07:00 AM

Heart Foundation GP liaison Joan Leighton and medical director Gerry Devlin see promise in new heart-failure drug Entresto
Entresto is not a ‘flash in the pan’ but a genuine breakthrough. In time, it will become a standard treatment for heart failure
A new drug for he
References
1. McMurray JV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.
2. Taylor CJ, Ordóñez-Mena JM, Roalfe AK, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ 2019;364:l223 (online 13 February).